11月21日，普莱柯盘中下跌2.03%，截至10:21，报13.54元/股，成交2581.59万元，换手率0.54%，总市 值46.86亿元。 资金流向方面，主力资金净流出28.53万元，大单买入337.15万元，占比13.06%，卖出365.68万元，占比 14.16%。 普莱柯所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：动物疫苗、宠物经 济、医药电商、禽流感药物、疫苗等。 截至9月30日，普莱柯股东户数1.67万，较上期减少7.26%；人均流通股20739股，较上期增加7.83%。 2025年1月-9月，普莱柯实现营业收入8.23亿元，同比增长8.04%；归母净利润1.57亿元，同比增长 47.86%。 分红方面，普莱柯A股上市后累计派现11.25亿元。近三年，累计派现5.68亿元。 机构持仓方面，截止2025年9月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第六大流通股东，持股547.16万股，相比上期增加202.17万股。香港中央结算有限公司位居第八大流通 股东，持股383.20万股，为新进股东。 责任编辑：小浪快报 普莱柯今年以来股价涨11.28 ...

分红方面，普莱柯A股上市后累计派现11.25亿元。近三年，累计派现5.68亿元。 机构持仓方面，截止2025年9月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第六大流通股东，持股547.16万股，相比上期增加202.17万股。香港中央结算有限公司位居第八大流通 股东，持股383.20万股，为新进股东。 资料显示，普莱柯生物工程股份有限公司位于河南省洛阳市洛龙区政和路15号，成立日期2002年6月22 日，上市日期2015年5月18日，公司主营业务涉及主要从事兽用生物制品、化学药品及中兽药的研发、 生产、销售及相关技术转让。主营业务收入构成为：禽用疫苗及抗体41.19%，猪用疫苗32.25%，化学 药品21.37%，功能性保健品等(宠物用)1.79%，宠物用疫苗1.38%，其中:宠物用1.26%，技术许可或转让 收入0.94%，其他(补充)0.83%，反刍动物用疫苗0.25%。 截至9月30日，普莱柯股东户数1.67万，较上期减少7.26%；人均流通股20739股，较上期增加7.83%。 2025年1月-9月，普莱柯实现营业收入8.23亿元，同比增长8.04%；归母净利润1.57亿 ...

11月20日，葵花药业涨0.00%，成交额3030.77万元。两融数据显示，当日葵花药业获融资买入额357.27 万元，融资偿还218.97万元，融资净买入138.30万元。截至11月20日，葵花药业融资融券余额合计1.40 亿元。 截至11月10日，葵花药业股东户数5.30万，较上期增加0.00%；人均流通股11018股，较上期增加 0.00%。2025年1月-9月，葵花药业实现营业收入16.84亿元，同比减少43.24%；归母净利润-3353.87万 元，同比减少105.72%。 分红方面，葵花药业A股上市后累计派现40.45亿元。近三年，累计派现17.52亿元。 机构持仓方面，截止2025年9月30日，葵花药业十大流通股东中，易方达中证红利ETF（515180）位居 第五大流通股东，持股340.08万股，相比上期增加23.96万股。香港中央结算有限公司位居第七大流通股 东，持股284.12万股，相比上期减少12.87万股。招商中证红利ETF（515080）位居第八大流通股东，持 股283.82万股，相比上期增加23.49万股。南方中证1000ETF（512100）位居第九大流通股东，持股 267.57万 ...

四、请详细说明你公司募集资金用途。 11月14日，中国证监会公布《境外发行上市备案补充材料要求(2025年11月10日—2025年11月14日)》。 中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求长春高新（000661）(000661.SZ) 补充说明公司募集资金用途、以及业务涉及AI大模型的具体情况等。据港交所9月29日披露，长春高新 技术产业(集团)股份有限公司(简称：长春高新)向港交所主板提交上市申请书，中信建投（601066）国 际为其独家保荐人。 中国证监会请长春高新补充说明以下事项，请律师核查并出具明确的法律意见： 一、请按照《监管规则适用指引——境外发行上市类第2号》补充说明你公司控股股东上层投资人吉林 省信政基金合伙企业(有限合伙)的穿透情况，是否存在法律法规规定禁止持股的主体。 二、请结合股票质押原因、合同履行情况、相关主体偿债能力等情况，补充说明本次发行上市前后，你 公司控股股东股权质押情况是否可能导致发行人控制权发生变化，是否导致发行人存在《境内企业境外 发行证券和上市管理试行办法》第八条规定的禁止性情形。 三、请补充说明你公司业务涉及AI大模型的具体情况，大模型的应用场 ...

二、请结合股票质押原因、合同履行情况、相关主体偿债能力等情况，补充说明本次发行上市前后，你 公司控股股东股权质押情况是否可能导致发行人控制权发生变化，是否导致发行人存在《境内企业境外 发行证券和上市管理试行办法》第八条规定的禁止性情形。 三、请补充说明你公司业务涉及AI大模型的具体情况，大模型的应用场景、具体功能等。 中国证监会请长春高新补充说明以下事项，请律师核查并出具明确的法律意见： 一、请按照《监管规则适用指引——境外发行上市类第2号》补充说明你公司控股股东上层投资人吉林 省信政基金合伙企业(有限合伙)的穿透情况，是否存在法律法规规定禁止持股的主体。 （原标题：新股消息 | 长春高新(000661.SZ)拟港股上市 中国证监会要求补充说明募集资金用途等） 智通财经APP获悉，11月14日，中国证监会公布《境外发行上市备案补充材料要求(2025年11月10日— 2025年11月14日)》。中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求长春高新 (000661.SZ)补充说明公司募集资金用途、以及业务涉及AI大模型的具体情况等。据港交所9月29日披 露，长春高新技术产业(集团)股份有限公司( ...

一、请按照《监管规则适用指引——境外发行上市类第2号》补充说明你公司控股股东上层投资人吉林 省信政基金合伙企业(有限合伙)的穿透情况，是否存在法律法规规定禁止持股的主体。 二、请结合股票质押原因、合同履行情况、相关主体偿债能力等情况，补充说明本次发行上市前后，你 公司控股股东股权质押情况是否可能导致发行人控制权发生变化，是否导致发行人存在《境内企业境外 发行证券和上市管理试行办法》第八条规定的禁止性情形。 三、请补充说明你公司业务涉及AI大模型的具体情况，大模型的应用场景、具体功能等。 四、请详细说明你公司募集资金用途。 五、请就你公司设立及历次股权变动是否合法合规出具结论性意见，目前仅核查重大方面。 智通财经APP获悉，11月14日，中国证监会公布《境外发行上市备案补充材料要求(2025年11月10日— 2025年11月14日)》。中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求长春高新 (000661.SZ)补充说明公司募集资金用途、以及业务涉及AI大模型的具体情况等。据港交所9月29日披 露，长春高新技术产业(集团)股份有限公司(简称：长春高新)向港交所主板提交上市申请书，中信建投 国际为 ...

Core Insights - On October 22, Kewang Pharmaceutical's stock rose by 1.17%, with a trading volume of 798.94 million yuan [1] - As of September 30, the number of shareholders decreased by 2.06% to 52,400, while the average circulating shares per person increased by 2.10% to 11,145 shares [2] Financing and Margin Trading - On October 22, Kewang Pharmaceutical had a financing buy amount of 6.15 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of -7.24 million yuan [1] - The total margin trading balance as of October 22 was 157 million yuan, with the financing balance at 155 million yuan, accounting for 1.70% of the circulating market value, which is below the 10th percentile level over the past year [1] - The company had a short selling repayment of 800 shares and a short selling amount of 900 shares on October 22, with a short selling balance of 127.93 million yuan, also below the 10th percentile level over the past year [1] Financial Performance - For the first half of 2025, Kewang Pharmaceutical reported a revenue of 1.31 billion yuan, a year-on-year decrease of 48.17%, and a net profit attributable to shareholders of 81.31 million yuan, down 83.28% year-on-year [2] - Cumulatively, the company has distributed 4.045 billion yuan in dividends since its A-share listing, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included E Fund CSI Dividend ETF, which held 3.1612 million shares, a decrease of 436,800 shares from the previous period [3] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 2.9699 million shares, while Southern CSI 1000 ETF also entered as a new shareholder with 2.6960 million shares [3]

Core Insights - Kain Technology's stock increased by 5.19% to 29.20 CNY per share, with a total market capitalization of 4.992 billion CNY as of October 14 [1] Company Overview - Kain Technology, established on August 20, 2008, is located in Beijing Economic and Technological Development Zone and was listed on February 8, 2021 [1] - The company focuses on the research, production, and sales of pharmaceuticals related to viral diseases [1] - Revenue composition: Chemical drugs 62.13%, Biological drugs 37.44%, Technical services 0.32%, CMO/CDMO 0.09%, Others 0.01% [1] Shareholder Insights - Zhonggeng Fund's Zhonggeng Value Leading Mixed Fund (006551) is among the top ten circulating shareholders of Kain Technology, having increased its holdings by 7,434 shares to a total of 4.5007 million shares, representing 2.63% of circulating shares [2] - The fund has realized an estimated floating profit of approximately 6.481 million CNY from this investment [2] Fund Performance - The Zhonggeng Value Leading Mixed Fund (006551) was established on December 19, 2018, with a current asset size of 2.374 billion CNY [3] - Year-to-date return is 52.97%, ranking 847 out of 8,162 in its category; the one-year return is 44.3%, ranking 1,694 out of 8,015; and since inception, the return is 238.18% [2] Fund Holdings - Kain Technology is the third-largest holding in the Zhonggeng Value Leading Mixed Fund, accounting for 5.04% of the fund's net value [4]

Core Viewpoint - Changchun High-tech has submitted an application for H-share listing on the Hong Kong Stock Exchange, which is expected to enhance its global strategy, accelerate internationalization, and improve its financing capabilities [1] Company Overview - Changchun High-tech is recognized as one of the few pharmaceutical companies in China that has achieved full industry chain capabilities in therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [3] - The company has developed a competitive and diversified product matrix, with over 45 commercialized drugs, including more than 20 first-in-class products globally or in China [4] Financial Performance - The projected sales revenue for Changchun High-tech's pharmaceutical products is expected to reach 12.7 billion RMB in 2024, maintaining over 10 billion RMB for four consecutive years [4] - Revenue figures for the years 2022 to 2025 show a steady increase, with revenues of 12.63 billion RMB in 2022, 14.57 billion RMB in 2023, and projected revenues of 13.47 billion RMB in 2024 and 6.60 billion RMB in the first half of 2025 [5] - Gross margins are projected to be 88%, 86%, 85.7%, and 83.4% for the years 2022, 2023, 2024, and the first half of 2025, respectively [5] Research and Development - The company has significantly increased its R&D investment, with a compound annual growth rate of 30.7% from 2012 to 2024, and R&D expenses are projected to account for 10.8%, 11.8%, 16.1%, and 17.5% of total revenue for the years 2022, 2023, 2024, and the first half of 2025, respectively [6] - Changchun High-tech aims to deepen its presence in various therapeutic areas through continuous innovation and R&D investment [6] Market Opportunities - The global pharmaceutical market is steadily developing, with the Chinese pharmaceutical market expected to grow significantly [7] - According to a Frost & Sullivan report, the Chinese innovative drug market is projected to reach 1.1715 trillion RMB in 2024 and 1.9505 trillion RMB by 2030, with a compound annual growth rate of 8.9% from 2024 to 2030 [8] - The company plans to enhance its global influence through high R&D investment, expanding its product portfolio, and improving manufacturing capabilities to meet market demand [8]

Core Viewpoint - Changchun High-tech has submitted an application for H-share listing on the Hong Kong Stock Exchange, which is expected to enhance its global strategy, accelerate internationalization, and improve its financing capabilities [1] Company Overview - Changchun High-tech is recognized as one of the few pharmaceutical companies in China with comprehensive capabilities in research, production, and commercialization across therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [3][4] - The company has developed a competitive and diversified product matrix, with over 45 commercialized drugs, including more than 20 first-in-class products globally or in China [4] Financial Performance - Revenue projections for Changchun High-tech show a steady increase, with expected revenues of 126.27 billion RMB in 2022, 145.66 billion RMB in 2023, and 134.66 billion RMB in 2024, maintaining over 100 billion RMB in sales for four consecutive years [4][5] - The gross profit margins are projected to be 88%, 86%, 85.7%, and 83.4% for the years 2022, 2023, 2024, and the first half of 2025, respectively [4][5] Research and Development - The company has significantly increased its R&D investment, with a compound annual growth rate of 30.7% from 2012 to 2024, and R&D expenses are projected to account for 10.8%, 11.8%, 16.1%, and 17.5% of total revenue for the years 2022, 2023, 2024, and the first half of 2025, respectively [6] - Changchun High-tech aims to deepen its presence in various therapeutic areas by continuously investing in innovation and accelerating the clinical development of candidate drugs [6] Market Opportunities - The global pharmaceutical market is steadily growing, with the Chinese innovative drug market expected to reach 1,171.5 billion RMB in 2024 and 1,950.5 billion RMB by 2030, reflecting a compound annual growth rate of 8.9% from 2024 to 2030 [8] - The company plans to enhance its global influence through high R&D investments, overseas licensing of innovative drugs, and diversification of its product portfolio [8]